Top Section/Ad
Top Section/Ad
Most recent
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
Pair enjoyed strong execution and tight pricing as US high grade credit remained resilient in the face of a sell-off in equity markets
More articles/Ad
More articles/Ad
More articles
-
Vaccine maker issued shares in oversubscribed deal to fund acquisition -
-
Existing shareholders took a large chunk of the deal, 30% of bidders left empty-handed
-
Calmer book builds than earlier trades hint at less guesswork over pricing
-
An end-of-year surge in deal-making has sparked predictions of a boom in leveraged buy-outs
-
Italian pharmacy group to refinance €460m of debt and pursue acquisitions
